1. Randomized control study of the use of faropenem for treating patients with pulmonary tuberculosis.
- Author
-
Shangguan, Yanwan, Guo, Wanru, Feng, Xuewen, Shi, Yunzhen, Li, Xiaomeng, Pan, Zhifen, Hu, Ming, Shi, Jichan, Ding, Cheng, Xia, Jiafeng, Hu, Wenjuan, Ji, Zhongkang, Zhao, Chengjie, Li, Yuecui, He, Zebao, Jin, Lingxiao, Tao, Xiaodong, Zhu, Xinming, Zhang, Xiaoqiang, and Song, Qun
- Subjects
- *
TUBERCULOSIS , *TUBERCULOSIS patients , *TREATMENT effectiveness , *SPUTUM examination - Abstract
• Faropenem has been proven useful in replacing ethambutol in the standard regimen. • Faropenem regimen showed a similar treatment success rate to the standard regimen. • Faropenem regimen is well tolerated and has fewer adverse events. • Oral β-lactam antibiotic can be a promising antituberculosis candidate. Faropenem has antituberculosis activity in vitro but its utility in treating patients with tuberculosis (TB) is unclear. We conducted an open-label, randomized trial in China, involving newly diagnosed, drug-susceptible pulmonary TB. The control group was treated with the standard 6-month regimen. The experimental group replaced ethambutol with faropenem for 2 months. The primary outcome was the treatment success rate after 6 months of treatment. Noninferiority was confirmed if the lower limit of a 95% one-sided confidence interval (CI) of the difference was greater than −10%. A total of 227 patients eligible for the study were enrolled in the trial group and the control group in a ratio of 1:1. Baseline characteristics of participants were similar in both groups. In the modified intention-to-treat population, 88.18% of patients in the faropenem group achieved treatment success, and 85.98% of those in the control group were successfully treated, with a difference of 2.2% (95% CI, −6.73-11.13). In the per-protocol population, treatment success was 96.04% in the faropenem group and 95.83% in the control group, with a difference of 2.1% (95% CI, −5.31-5.72). The faropenem group showed noninferiority to the control group in the 6-month treatment success rates. The faropenem group had significantly fewer adverse events (P <0.01). Our study proved that oral faropenem regimen can be used for the treatment of TB, with fewer adverse events. (Chinese Clinical Trial Registry, ChiCTR1800015959). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF